Canada · Delayed Price · Currency is CAD NeuPath Health Statistics
Total Valuation
NeuPath Health has a market cap or net worth of CAD 25.27 million. The enterprise value is 34.35 million.
| Market Cap | 25.27M |
| Enterprise Value | 34.35M |
Important Dates
The next estimated earnings date is Thursday, March 26, 2026.
| Earnings Date | Mar 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NeuPath Health has 56.16 million shares outstanding. The number of shares has increased by 0.15% in one year.
| Current Share Class | 56.16M |
| Shares Outstanding | 56.16M |
| Shares Change (YoY) | +0.15% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 2.91% |
| Owned by Institutions (%) | 11.12% |
| Float | 54.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.30 |
| PB Ratio | 1.19 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 8.81 |
| P/OCF Ratio | 6.73 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.41, with an EV/FCF ratio of 11.97.
| EV / Earnings | -62.11 |
| EV / Sales | 0.41 |
| EV / EBITDA | 7.41 |
| EV / EBIT | 14.82 |
| EV / FCF | 11.97 |
Financial Position
The company has a current ratio of 1.12, with a Debt / Equity ratio of 0.63.
| Current Ratio | 1.12 |
| Quick Ratio | 1.06 |
| Debt / Equity | 0.63 |
| Debt / EBITDA | 2.90 |
| Debt / FCF | 4.69 |
| Interest Coverage | 2.53 |
Financial Efficiency
Return on equity (ROE) is -1.21% and return on invested capital (ROIC) is -11.23%.
| Return on Equity (ROE) | -1.21% |
| Return on Assets (ROA) | 3.30% |
| Return on Invested Capital (ROIC) | -11.23% |
| Return on Capital Employed (ROCE) | 7.03% |
| Weighted Average Cost of Capital (WACC) | 3.41% |
| Revenue Per Employee | 567,108 |
| Profits Per Employee | -3,736 |
| Employee Count | 148 |
| Asset Turnover | 1.91 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NeuPath Health has paid 437,000 in taxes.
| Income Tax | 437,000 |
| Effective Tax Rate | 245.51% |
Stock Price Statistics
The stock price has increased by +106.82% in the last 52 weeks. The beta is 1.13, so NeuPath Health's price volatility has been higher than the market average.
| Beta (5Y) | 1.13 |
| 52-Week Price Change | +106.82% |
| 50-Day Moving Average | 0.49 |
| 200-Day Moving Average | 0.34 |
| Relative Strength Index (RSI) | 40.65 |
| Average Volume (20 Days) | 95,982 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NeuPath Health had revenue of CAD 83.93 million and -553,000 in losses. Loss per share was -0.01.
| Revenue | 83.93M |
| Gross Profit | 16.16M |
| Operating Income | 2.32M |
| Pretax Income | 178,000 |
| Net Income | -553,000 |
| EBITDA | 3.35M |
| EBIT | 2.32M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 4.63 million in cash and 13.45 million in debt, with a net cash position of -8.82 million or -0.16 per share.
| Cash & Cash Equivalents | 4.63M |
| Total Debt | 13.45M |
| Net Cash | -8.82M |
| Net Cash Per Share | -0.16 |
| Equity (Book Value) | 21.26M |
| Book Value Per Share | 0.37 |
| Working Capital | 1.55M |
Cash Flow
In the last 12 months, operating cash flow was 3.76 million and capital expenditures -887,000, giving a free cash flow of 2.87 million.
| Operating Cash Flow | 3.76M |
| Capital Expenditures | -887,000 |
| Free Cash Flow | 2.87M |
| FCF Per Share | 0.05 |
Margins
Gross margin is 19.25%, with operating and profit margins of 2.76% and -0.66%.
| Gross Margin | 19.25% |
| Operating Margin | 2.76% |
| Pretax Margin | 0.21% |
| Profit Margin | -0.66% |
| EBITDA Margin | 4.00% |
| EBIT Margin | 2.76% |
| FCF Margin | 3.42% |
Dividends & Yields
NeuPath Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.15% |
| Shareholder Yield | -0.15% |
| Earnings Yield | -2.19% |
| FCF Yield | 11.36% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NeuPath Health has an Altman Z-Score of 1.51 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.51 |
| Piotroski F-Score | 6 |